atients with abdominal aortic aneurysm (AAA) often have associated coronary artery disease (CAD), with a reported incidence of 46-71%. [1] [2] [3] [4] Preoperative coexistent CAD and cardiac symptoms have been identified as predictors of short-term survival of patients undergoing AAA repair. [5] [6] [7] [8] [9] The presence of CAD has also been shown to account for approximately one-third of late deaths after AAA repair. [5] [6] [7] [8] [9] It should be noted that these late deaths resulting from CAD outnumber all other causes of late mortality of patients undergoing AAA repair.
Despite such a significant effect on the short-and longterm survival of patients, evaluation of coexisting asymptomatic CAD is not emphasized in the AHA/ACC guideline for patients who are judged as having minor or no clinical risks for perioperative cardiovascular events and who have a functional capacity >4 METS. 10 Although surgical AAA repair may be safely performed even without preoperative evaluation of asymptomatic CAD in those with minor or no risks of perioperative cardiovascular events and preserved functional capacity, lack of evaluation for coexistent CAD may have a meaningful impact on the long-term outcome of these patients.
In the current study, we sought to determine the prevalence and prognosis of asymptomatic CAD patients with minor or no clinical risks for perioperative cardiovascular events and with preserved functional capacity undergoing AAA repair.
Methods

Study Population
From January 2002 to April 2006, a total of 388 consecutive patients underwent elective surgical repair of AAA at the National Cardiovascular Center in Japan. Patient demographic and clinical characteristics were retrospectively reviewed using hospital records. Informed consent was given by all patients in this study at the telephone canvas. Of these 388 patients, 172 were identified as having either major clinical risks (unstable coronary syndromes, decompensated heart failure (HF), significant arrhythmias, and severe valvular heart disease) or intermediate clinical risks (angina pectoris (AP), previous MI, compensated or prior HF, diabetes mellitus, and renal insufficiency with serum Cr >2 mg/dl). The remaining 216 patients were classified as having minor or no clinical risks for perioperative cardiovascular events and they were symptom-free of AP. Among them, 201 had preserved functional capacity >4 METS in their daily life. According to the AHA/ACC guideline 2002, these 201 patients did not have AP and did not require preoperative assessment of CAD.
Clinical Characteristics
Patient demographic and clinical characteristics, including age, sex, body mass index (BMI), smoking history, hypertension, glucose tolerance, dyslipidemia, and family history of CAD, were evaluated. Smoking history included past and current smoking; hypertension was defined as systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg for >2 measurements, or if the patient took medication for hypertension; impaired glucose tolerance was defined as a fasting glucose of 100-125 mg/dl (those with a fasting plasma glucose ≥126 mg/dl, hemoglobin A1c ≥6.5%, or current antidiabetic medications were defined as having diabetes mellitus, classified as the intermediate risk group according to the AHA/ACC guideline and excluded from the study population); dyslipidemia was defined as a fasting serum low-density lipoprotein (LDL)-cholesterol ≥140 mg/dl, or triglycerides ≥150 mg/dl, or high-density lipoprotein-cholesterol <40 mg/dl, or if the patient took lipid-lowering medications); family history of CAD was defined as history with CAD within second-degree relatives; obesity was defined as BMI ≥25 kg/m 2 .
Definitions of Comorbidities
Comorbidities, such as peripheral arterial disease (PAD), cerebral vascular disease (CVD), chronic kidney disease (CKD), and aortic diseases, were also evaluated. PAD was defined as a history of intermittent claudication, rest pain, gangrene, and ulcers, interventions to leg arteries, and a resting ankle-brachial pressure index <0.90. CKD was defined as estimated glomerular filtration rate (eGFR) <60 ml · min -1 · 1.73 m -2 calculated from the Modification of Diet in Renal Disease (MDRD) Study equation modified for Japanese, suggested by the Japanese Society of Nephrology {eGFR: for men = 0.741 × 175 × (age) -0.203 × (serum creatinine) -1.154 , for women = 0.741 × 175 × (age) -0.203 × (serum creatinine) -1.154 × 0.742}. 11 Cranial computed tomography (CT) and carotid echocardiography were performed for all patients and the images were read by experts in the neurology and radiology departments who were unaware of the patients' clinical details. The diagnosis of CVD was made when there were ischemic infarcts, such as large cortical infarcts or lacunar infarcts, or when there were silent obstructions or stenosis with a peak systolic velocity ≥150 cm/s by duplex scanning in at least 1 internal or common carotid artery, or when there was any obvious past evidence of treated brain infarction or carotid artery stenosis. The diagnosis of aortic aneurysm and dissection was made by contrast CT scanning. The definitions of thoracic aortic aneurysm (TAA) and AAA were: maximal diameter of aneurysm ≥40 mm or ≥30 mm, respectively. Aortic diseases included aortic emergencies such as aortic dissection and rupture of aortic aneurysm, and operations for aortic aneurysm or stenosis. We defined large AAA as ≥60 mm. CAD, coronary artery disease; BMI, body mass index; BP, blood pressure; ABPI, ankle-brachial pressure index; AAA, abdominal aortic aneurysm; LDL, low-density lipoprotein; HDL, high-density lipoprotein; FBS, fasting blood sugar; GFR, glomerular filtration rate; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin-receptor blocker; CCB, calcium-channel blocker.
Assessment and Treatment of Asymptomatic CAD
Most patients underwent clinical evaluation for the presence of asymptomatic CAD using dipyridamole thallium scintigraphy and coronary angiography (CAG) prior to AAA repair. CAG was performed for those with positive findings on scintigraphy or if they were considered not suitable for evaluation with scintigraphy (eg, those with associated chronic obstructive pulmonary disease (COPD)). Luminal diameter narrowing >50% in ≥1 major epicardial arteries or major branch was considered as clinically significant stenosis. Treatment of patients with significant CAD essentially followed the AHA/ACC 2002 guideline for the management of patients with chronic stable angina.
Assessment of Long-Term Outcome
The clinical findings were collected from hospital records. To evaluate prognosis, telephone canvass of patients, their surviving family members or their referring physicians was performed blindly by staff in the cardiovascular department. The primary endpoint was all-cause death, and cardiovascular death including cardiac, cerebrovascular, and vascular death. Unexplained sudden death was subsumed in cardiac death. The secondary endpoint was cardiac events, including cardiac death, acute coronary syndrome (ACS) such as nonfatal acute MI (AMI) and unstable AP (UAP), coronary revascularization for stable AP, and cardiac failure.
Statistical Analysis
JMP 5.1 software was used for all statistical analyses. Data was shown in mean ± standard deviation for continuous variables, and frequencies and percentages for categorical variables. Statistical significance was evaluated using a chisquare test for categorical data, and all categorized variables were included in the multivariate logistic regression analysis to clarify significant risk factors and calculate the odds ratios (OR) and 95% confidence interval (CI). Survival rates and cardiac-event-free rates were calculated by the KaplanMeier actuarial survival method, and log-rank statistics were used for the comparison between the groups. A P-value <0.05 was considered statistically significant.
Results
Patients' Characteristics
The characteristics of the 201 patients with minor or no clinical risks for perioperative cardiovascular events with preserved functional capacity >4 METS are shown in of 201 patients were found to have asymptomatic CAD (Figure 1) . As for the predictors of asymptomatic CAD, by univariate analysis, age ≥75 years and family history of CAD were identified as significant predictors of asymptomatic CAD ( 
Treatment of Asymptomatic CAD
All 59 patients with asymptomatic CAD received noninvasive medical and dietary therapy. In addition, 37 (62.7%) underwent invasive therapy, including 8 (13.6%) cases of coronary artery bypass grafting (CABG) and 29 (49.1%) of percutaneous coronary intervention (PCI). Among 33 patients with 1-vessel disease, 15 underwent PCI and 18 received noninvasive therapy alone; among 13 patients with 2-vessel disease, 1 underwent CABG, 9 had PCI and 3 had noninvasive therapy alone; among 12 patients with 3-vessel disease, 6 underwent CABG, 5 had PCI, and 1 had noninvasive therapy alone; 1 patient with left main trunk disease underwent CABG. At the time of discharge, aspirin and β-blockers were significantly more prescribed for patients with asymptomatic CAD (aspirin: 46 (78.0%) vs 24 (16.9%) P<0.0001; β-blockers: 32 (52.4%) vs 42 (29.6%) P=0.001). There were no differences between groups in the prescription of calcium-channel blockers (CCB: 43 (72.9%) in patients with asymptomatic CAD, and 94 (66.2%) in patients without asymptomatic CAD) or statins (19 (32.2%) in patients with asymptomatic CAD, and 37 (26.1%) in patients without asymptomatic CAD). The reason for the relatively lower rate of prescribed statins was that LDLcholesterol was usually well controlled by dietary therapy at the time of discharge.
Prognosis of Patients With and Without Asymptomatic CAD
The mean follow-up period was 35.4±15.3 months (range 1-65 months, median 34.0 months) and only 5 (2.5%) patients were lost. There were no perioperative deaths or cardiac events. Midterm mortality and cardiac events during follow-up are shown in Table 3 . As for death, approximately nine-tenths were non-cardiovascular deaths. With regard to the cardiac events, only 13 (6.5%) patients (4 (6.8 %) of 59 patients with asymptomatic CAD, and 9 (6.3%) of 142 patients without asymptomatic CAD), experienced cardiac events; 9 patients underwent revascularization: 5 (56%) for ACS (4 (44%) MI, 1 (11%) UAP) and 4 (44%) for stable AP with or without symptoms. Although there were no statistical differences between the 2 groups in either mortality or cardiac events, 5 patients with ACS all belonged to the non-asymptomatic CAD group. Of these 5 patients, only 1 underwent preoperative CAG because of a positive result on scintigraphy and did not have significant stenosis. After AAA repair, 2 patients had ACEI/ARB, β-blocker and CCB, 1 had ACEI/ARB and aspirin, 1 had ACEI/ARB and statin, and 1 had only ACEI/ARB. The Kaplan-Meier estimates of overall survival and cardiac events are shown in Figure 2 . The presence of asymptomatic CAD, when treated appropriately before AAA repair, did not significantly affect the incidence of death or cardiac events.
Discussion Prevalence of Asymptomatic CAD
In this population of AAA patients with minor or no clinical risks for perioperative cardiovascular events and with preserved functional capacity, who usually do not undergo preoperative coronary assessment according to the AHA/ACC guideline 2002, the prevalence of asymptomatic CAD was 29.4%. Considering that these patients did not have any evidence of AP, MI, HF, significant arrhythmias, diabetes mellitus, or renal insufficiency (Cr >2 mg/dl), this value seems very high.
Although many previous studies have shown the prevalence of coexistent CAD with AAA, there have been no reports referring to these low-risk patients. Hertzer et al 12 reported the results of routine CAG before AAA repair at the Cleveland Clinic, in which only 6% of patients had normal arteries; 29% had mild to moderate CAD; 29% had advanced compensated CAD; 31% had severe correctable CAD; and 5% had severe uncorrectable CAD. Furthermore, 18% of patients without clinically apparent CAD had severe correctable asymptomatic CAD. Utoh et al also performed routine CAG in patients before elective repair for AAA, and showed that 46% had severe CAD, 22% of whom were asymptomatic. 13 Kioka et al had a similar result in their study, in which the prevalence of symptomatic CAD accounted for 46% and asymptomatic CAD for 31%. 3 As the parent population and the definition of asymptomatic CAD were somewhat different in each study, it is difficult to exactly compare the results with our present data. However, what is certain is that there is a high prevalence of concomitant asymptomatic CAD in preoperative AAA patients, even those with minor or no clinical risk for perioperative cardiovascular events and with preserved functional capacity (>4 METS) according to the AHA/ACC guideline.
Prognosis of Asymptomatic CAD
With regard to prognosis, in previous studies the average is 35% of late deaths as cardiac in causation [5] [6] [7] [8] [9] 14, 15 and coexistent CAD could play a role in these deaths. The annual cardiac mortality rate and cardiac event rate ranged from 1.4% to 2.8% and 4.4% to 4.6%, respectively. [5] [6] [7] [8] [9] 14, 15 In the present study, only 13 (6.5%) cardiac events, including 3 (1.5%) cardiac deaths, all of which were unexplaoned sudden deaths, and 4 (2.0%) non-fatal MIs and 3 (1.5%) revascularizations, occurred in a mean 35 month-follow-up (2.2%/year cardiac events, 0.5%/year cardiac deaths, and 0.7%/year non-fatal MI), which were much better outcomes than in the previous reports. The main explanation for this discrepancy is the difference in the study population. the rate of late cardiac death, new cardiac event, new CABG/PCI, and nonfatal MI was 4.1%, 15%, 4.5%, and 4.8%, respectively. 16 Compared with that study, our data still showed a better outcome, and 2 explanations were prepared for this discrepancy. First, the previous study did not include no-risk patients and second, all patients in our study underwent preoperative coronary assessment and appropriate therapies, including noninvasive/invasive therapies, for asymptomatic CAD were initiated, which might possibly improve the outcome.
Several treatments, including noninvasive/invasive therapies, against CAD are recommended to improve the outcome. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] As for medication, Juul-Moller et al, reported the efficacy of aspirin in patients with stable AP, 17 and Pepine et al showed the efficacy of atenolol, even in patients with silent myocardial ischemia. 19 Many recent clinical trials support the effectiveness of statins. [27] [28] [29] [30] [31] As for revascularization, in previous studies CABG improved survival in patients with stenosis of the left main coronary artery, or 3-or 2-vessel disease including the proximal left anterior descending artery, compared with medical therapy. 32, 33 Although in the recent COURAGE study, PCI showed no benefit over optimal medical therapy with regard to the composite endpoint of death or MI, 34 in the SWISS II randomized controlled trial, patients with silent myocardial ischemia verified by stress imaging, and 1-or 2-vessel CAD, PCI compared with anti-ischemic drug therapy reduced the long-term risk of major cardiac events. 35 In our study, four-fifths of patients had aspirin, and ischemia was controlled by revascularization, β-blockers and CCBs. The rate of prescription of statins at discharge was not high because, in most patients, serum cholesterol was controlled well by strict dietary therapy during hospitalization. During follow-up, mortality and the occurrence of cardiac events were not different between the non-asymptomatic CAD group and asymptomatic CAD group and both of them had low rates. There is a possibility that appropriate therapy could help decrease the incidence of events. Furthermore, these therapies may help stabilize AP. When focused on the occurrence of ACS, including AMI, we found, although not significantly, a difference between each group, and the fact that no cases of ACS occurred in the asymptomatic CAD group may support the efficacy of appropriate therapy such as antiplatelet therapy and risk factor modification. The fact that 4 of 5 patients without CAD did not have aspirin or statin therapy, may help explain the effect of those medications in preventing ACS, which is supported by several other studies, 30, 31, 36 though it is difficult to draw an appropriate conclusion because of the small number of cases of ACS in the present study. Further studies are needed with larger populations and longer follow-up.
Many previous studies support that asymptomatic as well as symptomatic CAD patients should be treated, so the most important point is how to detect asymptomatic CAD patients in the AAA population. Indeed, the study population had low or no risk for perioperative cardiovascular events, but still had a higher possibility of having asymptomatic CAD. Operation for AAA is an opportunity for early detection of asymptomatic CAD. If no screening is done and no therapy is initiated, the prognosis could be worse. Considering the evidence discussed here, for patients with AAA and a low or no preoperative risk with preserved functional capacity, and who have a high prevalence of coexistent asymptomatic CAD, operation for AAA could be a very important opportunity to undergo screening and initiate appropriate therapy for asymptomatic CAD.
Study Limitations
First, this was a retrospective examination, and the study population and the number of endpoints might not be large enough to determine the statistical value. On this point, further studies with larger populations and longer follow-up are needed. Second, although appropriate CAD therapies included noninvasive/invasive therapies according to the AHA/ACC 2002 guideline for the management of patients with chronic stable AP, the details, such as doses of medications, type of device used for PCI, and operative procedures, were not shown. Finally, although some patients with negative findings by stress-induced perfusion imaging might have CAD when they have multivessel disease, the number would be few and the sensitivity of stress-induced perfusion imaging would be high enough to detect them. Although pharmachological stressed perfusion imaging was not performed in all the AAA patients and ischemia was not always confirmed, the result was almost the same in the multivariate analysis. In addition, patients without pharmachological stressed perfusion imaging included those with a relatively high possibility of CAD such as patients with large AAA needing urgent repair. In fact, patients without drug-induced perfusion imaging more often had multivessel disease, which could possibly induce ischemia. Furthermore, expert cardiology, vascular and radiology staff checked all angiographic images of the CAD patients who did not undergo perfusion imaging and detected stenosis that was severe enough to cause ischemia.
Conclusion
Although the guideline is very effective and economical for the perioperative management of AAA patients, even in those with low perioperative risk and preserved functional capacity, 29.4% in the present study had coexistent asymptomatic CAD, and half of them had multivessel disease. These patients are suspected candidates for coexistent asymptomatic CAD, especially if older than 75 years and/ or with a family history of CAD. Under appropriate therapy against CAD, the mid-term mortality rate and cardiac event rate are as well preserved as in patients without CAD. These findings underscore the importance of appropriate assessment and management for asymptomatic CAD in patients with AAA with low perioperative risks and preserved functional capacity.
Appropriate initiation of noninvasive and/or invasive therapy against CAD may decrease cardiac mortality and events in patients with AAA with low perioperative risks and preserved functional capacity, and therefore, coronary assessment and appropriate therapy should be performed.
